Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation

Gastroenterology. 2011 Aug;141(2):430-4. doi: 10.1053/j.gastro.2011.06.026. Epub 2011 Jun 23.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Colonic Neoplasms / drug therapy*
  • Drug Resistance, Neoplasm / drug effects*
  • Humans
  • JNK Mitogen-Activated Protein Kinases / drug effects*
  • Organoplatinum Compounds / pharmacology*
  • Oxaliplatin
  • TNF-Related Apoptosis-Inducing Ligand / pharmacology*
  • TNF-Related Apoptosis-Inducing Ligand / therapeutic use*

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • TNF-Related Apoptosis-Inducing Ligand
  • Oxaliplatin
  • JNK Mitogen-Activated Protein Kinases